

Medsafe Clozapine Survey 2023: Survey questions for medical doctors	
Question	Answer
Page 1: Your details	
What is your name?	Please answer below
What is your email address (or other contact details)?	Please answer below
What is your ethnicity?	Please answer below
Please select from below which best describes you.	<ul style="list-style-type: none"> • Individual who takes clozapine • Whānau, family and/or caregiver of an individual who takes clozapine • Medical doctor • Pharmacist • Nurse • Other healthcare professional
We intend to publish the submissions from this survey, but we will only publish your submission if you give permission. We will remove personal details such as email addresses and the names of individuals, and any other information that you tell us to remove. If you do not want your submission published, please let us know below.	<ul style="list-style-type: none"> • You may publish this submission. • Do not publish this submission.
Official Information Act responses: Your submission will be subject to requests made under the Official Information Act (even if it hasn't been published). If you want your personal details removed from your submission, please let us know below. We will take this into account when responding to requests under the Official Information Act.	<ul style="list-style-type: none"> • Include my personal details in responses to Official Information Act requests • Remove my personal details from responses to Official Information Act requests
Please let us know any other information that you would like us to remove from your response.	Please provide your answer below
Page 2: General questions	
Please describe your current role (Click all that apply).	<ul style="list-style-type: none"> • Psychiatrist or psychiatry registrar • General practitioner or general practitioner registrar • Other medical doctor (please provide further information below)
Please describe your clinical setting (Click all that apply).	<ul style="list-style-type: none"> • Inpatient psychiatric unit and/or hospital ward • Outpatient psychiatric service (excluding dedicated clozapine clinic) • Dedicated clozapine clinic • General practice • Other inpatient clinical setting (please provide further information below) • Other outpatient clinical setting (please provide further information below)
Approximately, how long have you been looking after people who take clozapine?	Duration (years)___
Approximately, how many people who are on clozapine are currently under your care?	<ul style="list-style-type: none"> • 1 – 10 • 11 – 20 • 21 – 30 • > 31 • Not applicable or other: please provide further information below
Of these people, approximately what proportion have been treated with clozapine for over 1 year on a continuous basis.	<ul style="list-style-type: none"> • 0 - 10% • 11 - 20% • 21 - 50% • > 51% • Not applicable
Which resources do you use for information about clozapine in your everyday role? (Click all that apply)	<ul style="list-style-type: none"> • Data sheet • Hospital protocols or guidelines

	<ul style="list-style-type: none"> National protocols or guidelines International protocols or guidelines Peer-reviewed journal articles Hospital medicine information services Ask colleagues in psychiatric medicine Ask colleagues in other specialities (e.g., haematology) Clozapine patient education resources (e.g., Consumer Medicines Information leaflet, Healthify (formerly Health Navigator)) Clozapine Patient Monitoring Services provided by pharmaceutical company Other resources: please provide further information below
Page 3: Clozapine side effects	
In general, how often do you ask patients if they are experiencing any potential side effects of clozapine? (you may select more than one option)	<ul style="list-style-type: none"> Weekly 4-weekly 12-weekly Ward rounds/ward visits Not applicable or other: please provide further information below. Please provide your answer below and/or any additional comments to the above question if necessary
Which clozapine side effects do you usually ask about? (Click all that apply)	<ul style="list-style-type: none"> Constipation Symptoms of infection Cardiovascular conditions Sedation Hypersalivation Other side effects: please provide further information below
In general, how are potential clozapine side effects identified? (Click all that apply)	<ul style="list-style-type: none"> Patients proactively inform you Asking patients directly Routine monitoring Not applicable or other If you would like to provide further information, please provide your answer below
If your patients have an adverse reaction to clozapine, do you report it to the Centre for Adverse Reactions Monitoring (CARM) New Zealand?	<ul style="list-style-type: none"> Yes No Not applicable or other If you would like to provide any additional information, please provide this below
Page 4: Constipation	
Approximately, what proportion of your current patients experience constipation with clozapine?	<ul style="list-style-type: none"> 0 - 10% 11 - 20% 21 - 50% > 51% Not applicable or other: please provide further information below
Do you routinely co-prescribe laxatives for patients taking clozapine?	<ul style="list-style-type: none"> Yes: regular laxative to be taken at least daily Yes: laxative to be taken if required No: please provide further information below Not applicable or other: please provide further information below Please provide your answer below
Do you have anything you would like to tell us about clozapine associated constipation? (e.g., patients needing hospital treatment or had to stop clozapine due to bowel problems, challenges with monitoring or treating constipation)	Please provide your answer below
Page 5: Haematological monitoring	
Approximately, what proportion of your current clozapine patients are on weekly, fortnightly, or 4-weekly haematological monitoring?	Weekly (%) Fortnightly (%) Every 4 weeks (%) Not applicable or other: please comment

Approximately, what proportion of your current patients have had to interrupt or discontinue clozapine due to an abnormal blood test result?	<ul style="list-style-type: none"> • 0 - 10% • 11 - 20% • 21 - 50% • >51% • Not applicable or other: please provide further information below
In patients who have experienced agranulocytosis with clozapine, how was this mostly identified?	<ul style="list-style-type: none"> • Routine blood test • Signs or symptoms that may be indicative of neutropenia resulting in additional blood test • Not applicable or other: please provide further information below
Is there anything you would like to tell us about the benefits or challenges around the mandatory haematological testing?	Please provide your answer below
How could the current haematological testing requirements for clozapine be improved?	Please provide your answer below
Page 6: Feedback	
Do you have any other feedback or information about clozapine that you would like to tell us?	Please provide your answer below.